Filing Flows › 8-K events › Traws Pharma
Traws Pharma: entry into a material definitive agreement
Form 8-K filed Oct 23, 2026 · items 1.01, 3.02
What the filing says
On October 23, 2026, Traws Pharma, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as of October 23, 2026, with Roth Principal Investments, LLC (“Roth Principal Investments”). Upo
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.02: +0.1% next session across 2,750. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Traws Pharma at a glance
Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%. The chart follows the revenue to costs, profit and cash.
Traws Pharma: every quarter, Q/Q and Y/Y, holders and guidance →
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.